Non-opioid pain drugs still fall short for aging patients

Chronic pain affects a large proportion of older adults, arising from joint conditions, nerve damage, or tissue injury. Opioids like morphine and oxycodone effectively reduce pain, but also cause dependence, confusion, and an elevated fall risk. That makes them especially problematic in older people. The demand for safer alternatives is high.

Researchers writing in Science explain why developing non-opioid pain drugs is so difficult. The pain system is complex and involves multiple overlapping signaling pathways. A drug that blocks one pathway often loses effectiveness because other pathways take over signal transmission. Clinical studies also measure pain relief in inconsistent ways, making it hard to compare findings across trials.

What works and what doesn’t

New compounds targeting sodium channels in nerve cells, the gateways through which pain signals travel, have been developed in recent years. Some show promise in early research but fall short in clinical trials due to side effects or insufficient efficacy. Biological drugs that block growth factors, such as NGF inhibitors, were also promising but led to joint damage in some patients.

For longevity research this matters: untreated chronic pain accelerates self-reported decline in physical function and mobility. Exercise, one of the best-supported lifestyle interventions for healthy aging, is harder to sustain with persistent pain. The inadequacy of current non-opioid options thus indirectly affects the broader domain of healthy aging.

Why it takes so long

Part of the delay lies in biology: the brain adapts to chronic pain, changing the mechanisms drugs are designed to block. Another part lies in the research process. Measuring pain in animal models differs from measuring it in people. That translation gap remains a persistent problem. Researchers call for better biomarkers and more standardized outcome measures in clinical trials.

Read the original article